ACT Brief: Embedding AI Across Operations, Faster Trial Decisions, and Voceryq Approval

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In a new Q&A, Rajneesh Patil of Syneos Health discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once. He explains where AI governance frameworks tend to fall short. He also argues that CROs must orchestrate AI ecosystems rather than simply aggregate them.
• A new feature article examines why faster trial data is not yet producing faster decisions. Data capture is no longer the bottleneck, since a signal can be generated instantly, but the harder question is whether the underlying data are clean, reconciled, standardized, and traceable. The article argues that whether the lag between signal and decision shrinks depends on signal design, AI governance, and vendor orchestration.
• FDA granted accelerated approval to INOVIO’s Voceryq to reduce how often adults need surgery for a rare disease that causes growths in the airway. The approval is based on a study of 32 patients, where 7 of 26 efficacy-evaluable patients had no surgery needed for 12 months after treatment. Continued approval depends on a confirmatory study, with a draft protocol due by the end of 2026.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.